GlaskoSmithKline opens pilot vaccine facility in eastern Melbourne that uses ground breaking technology for the delivery of vaccines


GlaxoSmithKline (GSK) opens a pilot vaccine facility in eastern Melbourne to further develop blow-fill-seal technology for vaccines.

The pilot facility is the result of GSK Australia collaborating with Monash University to develop a new way to use blow-fill-seal (BFS) to manufacture vaccines. GSK’s team in Melbourne worked with Monash University and global vaccine experts in Belgium to develop a new technique to preserve the sterility of vaccines in mass production.

The new BFS technology forms a container, fills and then seals it to maintain high assurance of sterility.

Putting the vaccine in (blow-fill-seal) containers has the potential to deliver the product in a more compact, robust container and it has a much smaller carbon footprint compared to current methodology.”  The process will reduce the cost of manufacturing vaccines and assist in making life-saving vaccines more affordable in developing countries.

Geoff McDonald - General Manager, GSK Australia

The project success was due to bringing together world-class infrastructure and a multi-disciplinary team.

To support the first run of commercial production of vaccines with the blow-fill-seal technology GSK has invested $7.7 million in the new facility.  It is supported by a $1 million grant through the Federal Government’s Manufacturing Transition Programme.

Monash leads the development of a world-class Medicines Manufacturing Innovation Centre (MMIC) as part of the Victorian Government’s Future Industries initiative

Based on a proven model of success between Monash University and GSK with the BFS project, the MMIC is a partnership initiative between the Victorian State Government and Monash Institute of Pharmaceutical Science (MIPS).

Located in the Parkville precinct, MMIC provides clients with access to world-class infrastructure and a multidisciplinary team to deliver economic impact and competitiveness to the state. It offers specialist analytical and formulation development services, utilising state-of-the art technology and expertise in product development and industrialisation in the areas of:

  • Pharmaceutical products
  • Veterinary products
  • Medical devices
  • Complimentary medicines
  • Nutraceutical
  • Cosmetics
  • Personal health care products

Key success include:

  • Oral solid form doses
  • Aerosol dose forms
  • Colloidal & dispersed systems, aqueous and lipid systems
  • Sterile aqueous liquids for blow-fill-seal manufacturing

Source: https://au.gsk.com/en-au/behind-the-science/innovation/vaccine-innovation-through-collaboration/

Find another case study